Torrent Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for TORNTPHARM, BSE:500420 Torrent Pharmaceuticals Ltd.

Torrent Pharmaceuticals Ltd.

27 Oct 2020

3681.80

0.71%

Torrent Pharmaceuticals

Buy: Torrent Pharmaceuticals Ltd.

Target

ICICI Securities Limited

Q2 revenues were in line with I-direct estimates whereas profitability was higher due to better-than-expected EBITDA margins, lower than expected interest expense and tax rate. Overhang pertaining to two US focused plants notwithstanding, Torrent continues to impress thanks to its robust margin profile that can be attributed to global portfolio that comprises ~65% branded generics. We expect a further improvement in this matrix, product rationalisation to further strengthen margins. The company's portfolio is finely balanced between India, Brazil, Germany and the US with India being...

Number of FII/FPI investors increased from 913 to 923 in Jun 2025 qtr.

Torrent Pharmaceuticals Ltd.

26 Oct 2020

3681.80

0.71%

Torrent Pharma

Hold: Torrent Pharmaceuticals Ltd.

Target

Sharekhan

Torrent reported a mixed performance for the quarter with results missing estimates. Revenues were flat YoY, while PAT grew 27% backed by OPM expansion. Outlook for the India business is healthy and Torrent looks to outperform the industry growth. Other markets such as US are under stress, while Europe performance is likely to improve, though over medium term. USFDA response on resolution for Dahej & Indrad is awaited. Rich valuation and recent run up in stock prices leaves limited upside. Torrent Pharmaceuticals Limited (Torrent) reported a mixed performance for Q2FY2021....

Torrent Pharmaceuticals Ltd. is trading above all available SMAs

Torrent Pharmaceuticals Ltd.

26 Oct 2020

3681.80

0.71%

Torrent Pharma

Sell: Torrent Pharmaceuticals Ltd.

Target

Dolat Capital

In 2QFY21, Torrent reported muted performance in its key export markets US (20% YoY decline), Brazil (17% YoY decline, primarily due to currency depreciation) while India (7% YoY growth) aided in flattish revenues for the quarter, in-line with our estimates. However, EBITDA margin at 31.5% were marginally better than expectation led by...

Number of FII/FPI investors increased from 913 to 923 in Jun 2025 qtr.

Torrent Pharmaceuticals Ltd.

26 Oct 2020

3681.80

0.71%

Operating leverage drives profitability

Neutral: Torrent Pharmaceuticals Ltd.

Target

Motilal Oswal

Torrent Pharma (TRP) delivered in-line 2QFY21 results. Revival in the Domestic Formulations (DF) / Germany businesses was offset by muted growth in the US and currency headwinds in Brazil. Reduced opex kept profitability elevated. With the outlook for India/Germany/Brazil improving, TRP is expected to outperform the industry on new launches / better traction in existing products. Growth in the US hinges on the Dahej/Indrad regulatory resolution. We raise our EPS estimate for FY21/FY22 by 4%/2% to factor in: a) the gradual normalization of opex on marketing in Branded Generics, b)...

Torrent Pharmaceutic.. has an average target of 3746.00 from 5 brokers.

Torrent Pharmaceuticals Ltd.

26 Oct 2020

3681.80

0.71%

Torrent Pharma

Buy: Torrent Pharmaceuticals Ltd.

Yes Securities

Chronic share is amongst highest and relative to Alembic we reckon Torrent exudes better confidence on growth hence shouldtradeatapremiumtoAlembic. Raised our FY22 EPS by ~12% to Rs91 on improved margin...

Number of FII/FPI investors increased from 913 to 923 in Jun 2025 qtr.

Torrent Pharmaceuticals Ltd.

04 Aug 2020

3681.80

0.71%

TORRENT PHARMA

Hold: Torrent Pharmaceuticals Ltd.

Target

Geojit BNP Paribas

Torrent Pharmaceuticals Limited (TRP) engages in the research, development, manufacturing and marketing of generic pharmaceutical formulations in India, US, Germany, Brazil and internationally. The company...

Torrent Pharmaceuticals Ltd. is trading above all available SMAs

Torrent Pharmaceuticals Ltd.

04 Aug 2020

3681.80

0.71%

Torrent Pharma

Hold: Torrent Pharmaceuticals Ltd.

Target

Sharekhan

Torrent Pharmaceuticals Limited (Torrent) reported strong performance for Q1FY2021. Revenues at Rs. 2,056 crore increased by 1.7% y-o-y on account of 2% growth in India business, while other geographies reported a decline. The chronic heavy portfolio in the Indian markets led to revenue growth. Operating profit at Rs. 661 crore increased by 22% y-o-y and was better than estimates. Operating profit margin (OPM) at 32% expanded by 540 bps y-o-y, backed by expansion in gross margins and lower other expenses. Strong operating performance percolated to the bottom line as well. Consequently, PAT for the quarter stood at Rs. 321 crore, up impressively by 49% y-o-y and was ahead...

Torrent Pharmaceutic.. has an average target of 3746.00 from 5 brokers.

Torrent Pharmaceuticals Ltd.

31 Jul 2020

3681.80

0.71%

Torrent Pharmaceuticals

Buy: Torrent Pharmaceuticals Ltd.

Recommendation Target

ICICI Securities Limited

India growth steady; acquisitions to enhance coverage Domestic branded formulations including CRAMs comprise 50% of sales. Acquisition of Elder Pharma's branded portfolio has added new therapies like neutraceuticals, gynaecology and helped fill up portfolio gaps. The Unichem acquisition has added branded portfolio comprising some power brands besides achievement of long term synergy benefits. Despite a YoY decline in IPM in Q1FY21 (-6% as per AIOCD), Torrent's portfolio has shown resilience (up 1% as per AIOCD) due to higher chronic contribution. We...

Torrent Pharmaceuticals Ltd. is trading above all available SMAs

Torrent Pharmaceuticals Ltd.

31 Jul 2020

3681.80

0.71%

Controlled opex drives profitability

Neutral: Torrent Pharmaceuticals Ltd.

Target

Motilal Oswal

31 July 2020 Despite COVID-19-led industry-wide slowdown in Domestic Formulations (DF), Torrent Pharma (TRP) outperformed owing to its strong presence in the Chronic segment. The Germany business is expected to see revival 2HFY21 onwards. Growth in the US hinges on the Dahej/Indrad regulatory resolution. from COVID-19-led weakness in the India/Brazil business, b) the Germany business returning to normal, and c) reduced opex aiding better profitability. We value TRP at 24x 12M forward earnings and roll our TP to INR2,565. Maintain Neutral on limited upside from current levels. ROW sales grew 31% YoY to INR2.3b (11% of sales), driving overall growth in revenue. India sales grew 2% YoY (INR9.3b; 45% of sales). Brazil revenue (7% of sales) was down 20% YoY to INR1.4b. In constant currency, Brazil sales were steady on a YoY basis.